Drug intelligence / Profile preview

SBC091-02

Development stage: Preclinical
Lead developer: SunRegen Healthcare
Modality: Small Molecules
Administration: Ophthalmic

Overview

SBC091-02 is a small molecule therapeutic candidate being developed by SunRegen Healthcare for the treatment of dry age-related macular degeneration (dry AMD). It is part of a development program that likely utilizes the company's lead compound, SBC003. The drug functions by targeting the neuroglobin pathway and chaperone proteins to exert neuroprotective, neurorescuing, and neurotrophic effects. By stabilizing or activating these pathways, SBC091-02 aims to mitigate retinal and optic nerve degeneration, which are central to the progression of dry AMD and other ophthalmic neurodegenerative conditions.

Targets

HSP60 (60 kDa heat shock protein, mitochondrial)NGB (Nucleolar GTP-binding protein 1)

Beyond the preview

Go deeper on SBC091-02.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SBC091-02.

Explore the full profile